SCHEMBL20394244

SCHEMBL20394244

CCOC(=O)c1ccc(Oc2ncccc2-c2cnccc2C)cc1

nearest known ligand 0.46

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
PDE10A Q9Y233 7/20 0.46
CCNC P24863 1/20 0.46
CDK8 P49336 1/20 0.46
NPC1 O15118 2/20 0.44
RAB9A P51151 2/20 0.44
SMN1; SMN2 Q16637 2/20 0.44
PDE4A P27815 1/20 0.43
PDE4B Q07343 1/20 0.43
KMT2A Q03164 1/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPT P10636 1/20 0.42
CYP1A2 P05177 1/20 0.42
POLB P06746 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20394320 0.90 PDE10A (0.46) PDE10ACCNCCDK8NPC1RAB9A
SCHEMBL20394485 0.89 PDE10A (0.52) PDE10ACCNCCDK8NPC1RAB9A
SCHEMBL20394161 0.89 PDE10A (0.45) PDE10ACCNCCDK8NPC1RAB9A
SCHEMBL18661529 0.88 PDE10A (0.60) PDE10ACCNCCDK8NPC1RAB9A
SCHEMBL20406628 0.86 PDE10A (0.57) PDE10ACCNCCDK8SMN1; SMN2PDE4A
SCHEMBL20394292 0.86 PDE10A (0.49) PDE10ARAB9APDE4APDE4BMAPT
SCHEMBL20406412 0.86 PDE10A (0.49) PDE10APDE4APDE4B
SCHEMBL20394267 0.83 CYP17A1 (0.45) PDE10AKMT2AMAPTL3MBTL1
SCHEMBL20394308 0.83 PDE10A (0.46) PDE10APDE4APDE4BKDM4EL3MBTL1
SCHEMBL20406409 0.81 MEN1 (0.50) PDE10AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3351533-B1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMA CO LTD (JP) 2025-07-23 EP disclosed
US-10647675-B2 Biaryl derivative and medicine containing same KAKEN PHARMACEUTICAL CO., LTD. (JP) 2020-05-12 US disclosed
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME KAKEN PHARMACEUTICAL CO., LTD. (JP) 2019-02-21 US disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed
EP-3351533-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME Kaken Pharmaceutical Co., Ltd. (JP) 2018-07-25 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10647675-B2 Biaryl derivative and medicine containing same MAN2B1, CBR3, MANBA PDE10A 4605/4885CCNC 1291/4885CDK8 3327/4885
US-20190055199-A1 BIARYL DERIVATIVE AND MEDICINE CONTAINING SAME MAN2B1, CBR3, MANBA PDE10A 4605/4885CCNC 1291/4885CDK8 3327/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.